Exact Sciences Stock Surges to 52-Week High

Exact Sciences Corporation has achieved a significant milestone, with its stock reaching a 52-week high of $73.09. This surge reflects a robust annual performance, with a 36.93% increase over the past year and notable gains year-to-date and in the last six months. Investor confidence remains high, bolstered by the company's recent Q3 2025 financial disclosures.

The company reported a strong third quarter for 2025, with earnings per share of $0.24, significantly beating the forecasted loss. Revenue also exceeded projections, reaching $851 million. This financial success was complemented by a 22% year-over-year growth in its core screening business, attributed to advancements in Cologuard rescreens and health plan care gap orders. Several financial firms maintained a Buy rating and raised their price targets following these results.

In addition to financial achievements, Exact Sciences has demonstrated its commitment to innovation with the successful clinical validation of its Oncoguard Liver blood test. This new test showed a seven-fold increase in sensitivity for early-stage liver cancer detection compared to traditional ultrasound methods. These advancements underscore the company's expanding role in the cancer diagnostics sector.